Medicare Part D Step Therapy: Exception Request Process for Denied Prescriptions

What Medicare Part D Step Therapy Means for Your Clients

Medicare Part D step therapy is a coverage rule that requires beneficiaries to try a lower-cost, preferred prescription drug before the plan will cover a more expensive, non-preferred medication for the same condition. For financial advisors guiding clients age 60 and older, understanding how to navigate this process is essential when a client's prescribed medication is denied at the pharmacy counter.

Step therapy, sometimes called a "fail first" protocol, is a cost-management tool used by Medicare Part D plans. When a plan requires step therapy, the client must first use a preferred drug — typically a generic or lower-tier brand — to treat their condition. Only if that drug proves ineffective or causes side effects will the plan cover the originally prescribed medication.¹

In 2025, 54.8 million of the 68.8 million Medicare beneficiaries are enrolled in Medicare Part D plans, meaning the majority of your clients will encounter these protocols at some point.² The challenge arises when a client's physician believes the preferred drug is inappropriate due to a pre-existing condition, a known adverse reaction, or a lack of efficacy based on the client's medical history.

For advisors, the practical concern is continuity of care. A client who has been stable on a specific medication for years may suddenly face a denial at the pharmacy because the plan's formulary has changed for the new plan year. This creates a gap in treatment that can lead to hospitalizations, emergency room visits, or worsening chronic conditions — all of which have financial consequences for the client's retirement budget.

When and Why to Pursue a Step Therapy Exception

A step therapy exception request is the formal process to bypass the step therapy requirement. CMS requires Part D plans to grant these exceptions when the enrollee has already tried and failed the preferred drug, or when the preferred drug is contraindicated or likely to cause an adverse reaction.¹

Advisors should help clients identify three specific scenarios that justify an exception request. First, the client has a documented history of trying the preferred drug with poor results — for example, a blood pressure medication that caused severe dizziness. Second, the client has a comorbid condition that makes the preferred drug unsafe, such as a beta-blocker prescribed for heart failure that could worsen asthma. Third, the client is currently stable on a non-preferred medication and switching would risk destabilizing their condition.

A 67-year-old client who takes a brand-name cholesterol medication may suddenly face a step therapy requirement when her Part D plan moves that drug to a higher tier. Her physician can submit an exception request citing her documented history of muscle pain with the generic alternative. The key is timing: submit the request before the new plan year begins, not after the denial at the pharmacy.

The Exception Request Form: What Prescribers Must Include

The Part D exception request form is the critical document that the prescribing physician must complete and submit to the plan. Under CMS Chapter 18 guidance, plans must make these forms available upon request to both enrollees and prescribing physicians.³

A complete exception request must include three elements. First, a written statement from the prescriber explaining the medical necessity for the non-preferred drug. This statement should cite specific clinical reasons — not general preferences — such as "patient experienced rhabdomyolysis on atorvastatin" rather than "patient prefers brand-name medication." Second, supporting clinical documentation, which may include lab results, progress notes, or a history of adverse reactions. Third, the prescriber's signature and contact information.

The most common documentation failure is a vague supporting statement. A physician who writes "patient cannot take generic" without providing clinical evidence will likely receive a denial. Advisors should coach clients to ask their physician for a detailed letter that includes specific dates, symptoms, and test results. For example, "On March 15, 2025, patient was prescribed simvastatin 20 mg. After 14 days, patient reported severe muscle pain. Creatine kinase levels were elevated at 450 U/L. Medication was discontinued on March 30, 2025."

Navigating the 72-Hour Standard vs. 24-Hour Expedited Review

CMS mandates specific response timelines for Part D exception requests. Plans must respond to standard coverage determination and exception requests within 72 hours. Expedited requests require a response within 24 hours when a prescriber determines that standard timelines could seriously jeopardize life, health, or ability to maintain maximum function.¹

The distinction between standard and expedited review is critical for advisors to understand. A standard request is appropriate when the client has a 30-day or 90-day supply of their current medication and can wait three days for a decision. An expedited request is necessary when the client has run out of medication or is scheduled for a procedure that requires the drug.

To request an expedited review, the prescriber must submit a statement explaining why the 72-hour timeline poses a risk. For instance, "Patient requires this medication to prevent stroke. A three-day delay increases the risk of a cerebrovascular event." The plan must grant the expedited status if the prescriber makes this determination — the plan cannot second-guess the physician's clinical judgment on urgency.

Advisors should help clients prepare for both scenarios. Keep a copy of the exception request form and the prescriber's supporting statement. Note the date and time of submission. If the plan does not respond within the required window, the advisor can escalate to the plan's customer service department and cite the CMS regulatory requirement.

If the Plan Denies: The Appeal Process and Independent Review

If a coverage determination is denied, the enrollee has the right to a formal appeal through the Part D plan, then to an independent review entity outside the plan, and further to an administrative law judge review if the amount in controversy meets the threshold.¹

The appeal process has five levels. Level one is a redetermination by the Part D plan itself. The client or their prescriber must file the appeal within 60 days of the denial notice. Level two is a reconsideration by an independent review entity (IRE) contracted by CMS. If the IRE upholds the denial, the client can proceed to level three, an administrative law judge (ALJ) hearing, provided the amount in controversy exceeds a minimum threshold that adjusts annually. Level four is the Medicare Appeals Council, and level five is federal district court.

For advisors, the most actionable level is the first redetermination. Many clients give up after the initial denial, not realizing that the plan itself may reverse its decision upon review. The key is to submit additional documentation that was missing from the initial request. For example, if the initial exception request lacked lab results showing the adverse reaction, the appeal should include those results along with a cover letter from the prescriber.

Tracking Client Outcomes and Avoiding Future Coverage Gaps

Advisors who track their clients' Part D exception outcomes can identify patterns that prevent future denials. The most common pattern is a formulary change at the start of a new plan year. A client who has been stable on a medication for years may find it moved to a higher tier or placed under step therapy in January.

To avoid coverage gaps, advisors should review each client's Part D plan's formulary annually during the Medicare Open Enrollment Period (October 15 to December 7). If a client's medication is subject to step therapy in the new plan year, the advisor can help the client request an exception before January 1. This proactive approach ensures the client has a 90-day supply of their medication while the exception is processed.

Another strategy is to document the client's medication history in a format that the prescriber can easily attach to an exception request. A simple one-page summary listing the medication name, dosage, start date, and any adverse reactions saves the physician time and reduces the risk of a vague supporting statement.

For advisors using a client management system, create a field for "Part D exception status" and set a reminder to check it 60 days before the plan year ends. This small administrative step can prevent a crisis when a client discovers their medication is no longer covered.

Your Next Step

Pull client files now and flag anyone taking a brand-name medication that may face step therapy in the next plan year. Request formulary exception letters from prescribers proactively — before January 1, not after a pharmacy denial. Build a one-page medication history summary for each affected client: medication name, dosage, start date, adverse reactions. Set a reminder 60 days before open enrollment to review Part D formulary changes and initiate exception requests while clients have a 90-day supply runway. This five-minute quarterly review prevents a denial and the cascade of appeals that follows.